26787-78-0 Usage
Uses
Used in Pharmaceutical Industry:
Amoxicillin is used as an antibiotic for the treatment of various bacterial infections. It works by inhibiting bacterial transpeptidase, an enzyme essential for bacterial cell wall synthesis, leading to cell lysis and death.
Used in Medical Treatment:
Amoxicillin is used as a therapeutic agent to combat a wide range of bacterial infections, including respiratory, urinary, skin, and ear infections, among others. Its effectiveness in treating these infections makes it a valuable tool in the medical field.
Brand Names:
Amoxicillin is available under various brand names, such as Amoxil (GlaxoSmithKline), Dispermox (Ranbaxy), Larotid (GlaxoSmithKline), and Trimox (Apothecon).
Brand Name(s)
Amoxicillin Amoxi-Tabs, Amoxi-Drops, Amoxi-Inject, Robamox-V, Biomox, and other brands; Amoxil, Trimox, Wymox, Polymox, (human forms); Amoxicillin trihydrate
Originator
Arnoxil,Bencard,UK,1972
Indications
Amoxycillin, like ampicillin, has a broad spectrum of use.
Indications for use are the same as with ampicillin. Synonyms of this drug are amoxican, amoxil, larotid, robamox, trimox, vimox, utimox, and others.
Undoubtedly, analogs of ampicillin that are substituted at the amine fragment of phenylglycine (azolcillin, mezlocillin, piperacillin) should be included in this same group of compounds.
Manufacturing Process
Ethyl chlorocarbonate (2.2 ml) was added to an ice cold solution of O,N-dibenzyloxycarbonyl-p-oxy-dl-α-aminophenylacetic acid (10 grams) and
triethylamine (3.85 ml) in dry acetone (193 ml). The mixture was stirred at
0°C for 5 minutes during which triethylamine hydrochloride precipitated. The
suspension was cooled to -30°C and stirred vigorously while adding as rapidly
as possible an ice cold solution of 6-aminopenicillanic acid (5.85 grams) in 3%
aqueous sodium bicarbonate (193 ml), the temperature of the mixture never
being allowed to rise above 0°C. The resulting clear solution was stirred for 30
minutes at 0°C, and then for a further 30 minutes, without external cooling,
and finally extracted with diethyl ether (3 x 200 ml) only the aqueous phase
being retained.
This aqueous solution was brought to pH 2 by the addition of hydrochloric acid
and the 6-(O,N-dibenzyloxycarbonyl-p-oxy-dl-α-
aminophenylacetamido)penicillanic acid so liberated was extracted into diethyl
ether (50 ml and 2 portions of 30 ml). The ether phase was washed with
water (3 x 5 ml) and the water washings were discarded.
Finally, the penicillin was converted to the sodium salt by shaking the ether
solution with sufficient 3% sodium bicarbonate to give a neutral aqueous
phase, separating the latter and evaporating it at low pressure and
temperature below 20°C. The product was finally dried over phosphorus
pentoxide in vacuo to give sodium 6-(O,N-dibenzyloxycarbonyl-p-oxy-dl-α-
aminophenylacetamido)-penicillanate (9.2 grams).
A suspension of palladium on calcium carbonate (36 grams of 5%) in water
(150 ml) was shaken in an atmosphere of hydrogen at room temperature and
atmospheric pressure for 1 hour. A neutral solution of sodium 6-(O,Ndibenzyloxycarbonyl-
p-oxy-dl-α-aminophenylacetamido)penicillanate (9
grams) in water (100 ml) was then added and shaking in hydrogen was
resumed for one hour. The suspension was then filtered and the collected
catalyst was washed well with water without being allowed to suck dry
between washings. The combined filtrate and washings were then brought to
pH 6.5 with dilute hydrochloric acid and evaporated to dryness at reduced
pressure and temperatures below 20°C. The product was finally dried over
phosphorus pentoxide in vacuo to give a solid (5.4 grams) containing 6-(phydroxy-
dl-α-aminophenylacetamido)penicillanic acid.
Therapeutic Function
Antibacterial
Antimicrobial activity
The antibacterial spectrum is identical to that of ampicillin
and there are few differences in antibacterial activity
. Like ampicillin, amoxicillin is unstable to most
β-lactamases. It has useful activity against Helicobacter pylori
(<1% resistance), and is included in most combination regimens
for the treatment of H. pylori infections.
Acquired resistance
There is complete cross-resistance with ampicillin. Its
action against many β-lactamase-producing strains can be
restored by co-administration with β-lactamase inhibitors.
Flammability and Explosibility
Nonflammable
Contact allergens
Amoxicillin is both a topical and a systemic sensitizer.
Topical sensitization occurs in health care workers.
Systemic drug reactions are frequent, such as urticaria,
maculo-papular rashes, baboon syndrome, acute generalized
exanthematous pustulosis, or even toxic epidermal
necrosis. Cross-reactivity is common with
ampicillin, and can occur with other penicillins.
Pharmacokinetics
Oral absorption: 75–90%
Cmax 500 mg oral: 5.5–7.6 mg/L after 1–2 h
500 mg intramuscular: c. 14 mg/L after 1–2 h
Plasma half-life: 1 h
Volume of distribution: 0.3 L/kg
Plasma protein binding: 17–20%
Absorption and distribution
Oral absorption produces over twice the peak concentration
achieved by comparable doses of ampicillin, allowing
less frequent dosing intervals. Absorption is unaffected by
food.
It is well-distributed in multiple body fluids, including
pleural, peritoneal and middle ear fluid. It does not penetrate
well into the CSF.
Metabolism and excretion
Some 10–25% is converted to the penicilloic acid.
Between 50% and 70% of unchanged drug is recovered
in the urine in the first 6 h after a dose of 250 mg. Plasma
levels are elevated and prolonged by the administration of
probenecid.
Clinical Use
Amoxicillin, 6-[D-(-)-α-amino-p- hydroxyphenylacetamido]penicillanic acid (Amoxil, Larotid, Polymox), a semisyntheticpenicillin introduced in 1974, is simply the p-hydroxyanalog of ampicillin, prepared by acylation of 6-APA with phydroxyphenylglycine.Its antibacterial spectrum is nearly identical with that ofampicillin, and like ampicillin, it is resistant to acid, susceptibleto alkaline and β-lactamase hydrolysis, andweakly protein bound. Early clinical reports indicated thatorally administered amoxicillin possesses significantadvantages over ampicillin, including more complete GIabsorption to give higher plasma and urine levels, lessdiarrhea, and little or no effect of food on absorption.50Thus, amoxicillin has largely replaced ampicillin for thetreatment of certain systemic and urinary tract infectionsfor which oral administration is desirable. Amoxicillin isreportedly less effective than ampicillin in the treatment ofbacillary dysentery, presumably because of its greater GIabsorption. Considerable evidence suggests that oral absorptionof α-aminobenzyl–substituted penicillins (e.g.,ampicillin and amoxicillin) and cephalosporins is, at leastin part, carrier mediated, thus explaining their generallysuperior oral activity.Amoxicillin is a fine, white to off-white, crystallinepowder that is sparingly soluble in water. It is available invarious oral dosage forms. Aqueous suspensions are stablefor 1 week at room temperature.
Clinical Use
Isolates should be tested for susceptibility before use, especially
for serious infections.Ear, nose and throat infections other than pharyngitis, which may mask
glandular
fever
Tracheobronchitis, bronchitis, pneumonia
Genitourinary tract infections, including gonorrhea
Infections of skin and soft tissues due to streptococci and susceptible
staphylococci
Helicobacter pylori infection (in combination with a proton pump inhibitor
and at least one other antimicrobial agent such as clarithromycin)
Prophylaxis of endocarditis in patients undergoing dental treatment and
other procedures
Side effects
Amoxicillin is generally well tolerated, side effects being those
common to penicillins, but including non-allergic rashes in
patients with glandular fever. As the drug is well absorbed,
diarrhea is generally infrequent and rarely sufficiently severe
to require withdrawal of treatment.
Synthesis
Amoxycillin, [2S-[2α,5α,6β(S)]]-3,3-dimethyl-7-6-[[amino-(4-hydroxyphenyl)-acetyl]amino]-4-thia-1-azabicyclo[3.2.0]-heptan-2-carboxylic acid (32.1.1.21), is synthesized in two ways. The first uses an enamine protection of the amino group of
4-hydroxyphenylglycine, which begins with the sodium salt of 4-hydroxyphenylglycine,
which is reacted with the acetoacetic ester to form an enamine—the sodium salt of a phydroxyphenyl acetic acid, α-[(3-ethoxy-1-methyl-3-oxo-1-propenyl)amino]-4-hydroxy-
(32.1.1.19). Reacting the resulting aminocrotonate with the ethyl chloroformate in
N-methylmorpholine gives the corresponding mixed anhydride (32.1.1.20), which is reacted
with trimethylsilyl ester of 6-APA. The second method uses a direct reaction of D-(-)-2-(4-hydroxyphenyl)glycine chloride
hydrochloride with trimethylsylil ester of 6-APA.The trimethylsilyl ester of 6-APA needed for the reaction is in turn synthesized by reacting trimethylchlorosilylane with 6-APA in the presence of trimethylamine.
Veterinary Drugs and Treatments
Amoxicillin/potassium clavulanate tablets and oral suspension
products are approved
for use in dogs and cats for the treatment of
urinary tract, skin and soft tissue infections caused by susceptible
organisms. It is also indicated for canine periodontal disease due to
susceptible strains of bacteria.
Veterinary Drugs and Treatments
The aminopenicillins have been used for a wide range of infections
in various species. FDA-approved indications/species, as well as
non-approved uses, are listed in the Dosages section below.
Drug interactions
Potentially hazardous interactions with other drugs
Amoxicillin can reduce the excretion of methotrexate
(increased risk of toxicity).
Metabolism
Amoxicillin is metabolised to a limited extent to
penicilloic acid which is excreted in the urine. About 60%
of an oral dose of amoxicillin is excreted unchanged in
the urine by glomerular filtration and tubular secretion.
Probenecid reduces renal excretion. High concentrations
have been reported in bile; some may be excreted in the
faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 26787-78-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,7,8 and 7 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 26787-78:
(7*2)+(6*6)+(5*7)+(4*8)+(3*7)+(2*7)+(1*8)=160
160 % 10 = 0
So 26787-78-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H19N3O5S.3H2O/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;;;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);3*1H2/t9-,10-,11+,14-;;;/m1.../s1
26787-78-0Relevant articles and documents
Purification of amoxicillin trihydrate by impurity-coformer complexation in solution
Hsi, Kay Huai Ying,Concepcion, Anthony Joseph,Kenny, Meghan,Magzoub, Amna Ahmed,Myerson, Allan S.
, p. 6776 - 6781 (2013)
In this work, we demonstrated the purification of amoxicillin trihydrate (AMCT) by the formation of 4-hydroxyphenylglycine (4HPG)-coformer complex in solution. Without advanced knowledge of cocrystal formation of 4HPG, a workflow was established to choose
Amoxicillin Inactivation by Thiol-Catalyzed Cyclization Reduces Protein Haptenation and Antibacterial Potency
Ariza, Adriana,Blanca, Miguel,Ca?ada, F. Javier,Monta?ez, María I.,Pérez-Sala, Dolores,Pajares, María A.,Sánchez-Gómez, Francisco J.,Torres, María J.,Zimmerman, Tahl
, (2020)
Serum and cellular proteins are targets for the formation of adducts with the β-lactam antibiotic amoxicillin. This process could be important for the development of adverse, and in particular, allergic reactions to this antibiotic. In studies exploring protein haptenation by amoxicillin, we observed that reducing agents influenced the extent of amoxicillin-protein adducts formation. Consequently, we show that several thiol-containing compounds, including dithiothreitol, N-acetyl-L-cysteine, and glutathione, perform a nucleophilic attack on the amoxicillin molecule that is followed by an internal rearrangement leading to amoxicillin diketopiperazine, a known amoxicillin metabolite with residual activity. Increased diketopiperazine conversion is also observed with human serum albumin but not with L-cysteine, which mainly forms the amoxicilloyl amide. The effect of thiols is catalytic and can render complete amoxicillin conversion. Interestingly, this process is dependent on the presence of an amino group in the antibiotic lateral chain, as in amoxicillin and ampicillin. Furthermore, it does not occur for other β-lactam antibiotics, including cefaclor or benzylpenicillin. Biological consequences of thiol-mediated amoxicillin transformation are exemplified by a reduced bacteriostatic action and a lower capacity of thiol-treated amoxicillin to form protein adducts. Finally, modulation of the intracellular redox status through inhibition of glutathione synthesis influenced the extent of amoxicillin adduct formation with cellular proteins. These results open novel perspectives for the understanding of amoxicillin metabolism and actions, including the formation of adducts involved in allergic reactions.
Preparation method of amoxicillin
-
, (2019/12/25)
The invention provides a preparation method of amoxicillin. The amoxicillin is obtained by synthesis of amino protected raw materials, the reaction route is short, product purity is high, operation iseasy, and wide industrial application prospects are achieved.
Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof
-
, (2011/07/08)
The present invention relates to a pharmaceutical composition and its preparation method for the eradication of Helicobacter pylorif in the forms of effervescent tablet, suspension or powder. The pharmaceutical composition comprises an effective dose of β-lactam antibiotic, an effective dose of macrolide antibiotic, an effective dose of antacid such as proton pump inhibitor and H2 blocker, and a pharmaceutical acceptable carrier. An effective dose of alkaline substance such as carbonate or bicarbonate can be added to increase the pH of the stomach when the PPI antacid is used, which can protect the degradation of acid-labile antibiotics or PPI to further increase the bioavailability of the pharmaceutical composition for the purpose of Helicobacter pylori eradication.
Process and device for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules
-
, (2008/06/13)
The present invention provides a process for preparing liquid pharmaceutical formulations on demand from tablets and capsules.
Method of using deuterated calcium channel blockers
-
, (2008/06/13)
Therapeutic methods and compositions using deuterated enriched 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester and other deuterated dihydropyridine compounds are described. The deuterated compounds exhibit enhanced efficacy in blocking calcium channels over non-deuterated dihydropyridines.
Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
-
, (2008/06/13)
A method of use of clavulanate to enhance the antibacterial activity of an antibacterial compound against microorganisms having an antibiotic resistance mechanism other than β-lactamase enzyme mediated resistance. Pharmaceutical formulations and methods of use which exploit this method.
Penicillin acylase in the industrial production of β-lactam antibiotics
Brugging, Alle,Roos, Eric C.,De Vroom, Erik
, p. 128 - 133 (2013/09/08)
Immobilized penicillin acylase is a biocatalyst suitable for the kinetically controlled industrial synthesis of semi-synthetic antibiotics in aqueous environments. Amoxiciliin and ampicillin are obtained by condensing 6-aminopenicillanic acid with the amide or ester of D-( - )-4-hydroxyphenyIglycine and D-( - )phenylglycine, respectively. Similarly, the cephalosporin antibiotics cefadroxil and cephalexin can be obtained from 7-aminodesacetoxycephalosporanic acid.
Enhancement of the efficacy of nifedipine by deuteration
-
, (2008/06/13)
A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
Pharmaceutical thermal infusion process
-
, (2008/06/13)
A chewable tablet comprises a medicament dispersed in a chewable base, such as mannitol, together with an effervescent couple, such as citric acid--sodium bicarbonate. The combination of effervescence and chewability with optional flavorings improves the taste characteristics of the medicament in oral administration. A distintegrant such as microcrystalline cellulose may be added to give the patient the option of dispersing the tablet in water.